Home » Merrimack Gets FDA Orphan Drug Designation for MM-141
Merrimack Gets FDA Orphan Drug Designation for MM-141
Merrimack Pharmaceuticals has secured orphan drug designation from the FDA for its investigational drug candidate MM-141 to treat pancreatic cancer.
Pharmaceutical Business Review
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May